Cargando…
Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
BACKGROUND: Insulin glargine 300 U/mL (Gla-300) contains the same active ingredient as glargine 100 U/mL (Gla-100), and provides the same number of units in one-third of the volume. The SoloSTAR(®) injector pen has been modified to ensure accurate administration of this reduced volume and to improve...
Autores principales: | Pohlmeier, Harald, Berard, Lori, Brulle-Wohlhueter, Claire, Wu, Junlong, Dahmen, Raphael, Nowotny, Irene, Klonoff, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478028/ https://www.ncbi.nlm.nih.gov/pubmed/27664062 http://dx.doi.org/10.1177/1932296816668877 |
Ejemplares similares
-
Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey
por: Klonoff, David, et al.
Publicado: (2015) -
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014) -
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
por: Ritzel, R, et al.
Publicado: (2015) -
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes
por: Ritzel, Robert, et al.
Publicado: (2017) -
Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient‐level pooled analysis of EDITION 1, 2 and 3
por: Bonadonna, Riccardo C., et al.
Publicado: (2018)